logo
Plus   Neg
Share
Email

5 Top Gainers In Healthcare Sector (TROV, FULC, ARDX…)

pharmaup-aug19-lt.jpg

The following are some of today's top gainers in the pharma/biotech sector.

1. TrovaGene Inc. (TROV)

Trovagene is a clinical-stage oncology therapeutics company.

Gained 43.54% to close Monday's (Aug.19) trading at $3.00. The stock is up over 110% in the last 4 trading days.

News: No news

Clinical Trials:

The Company's lead product candidate is Onvansertib, which is being tested:

-- in combination with either low-dose cytarabine (LDAC) or decitabine for the treatment of Acute Myeloid Leukemia (AML) under a phase Ib/II trial.
-- in combination with Zytiga for the treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) in a phase II trial.
-- and in a phase Ib/II study in combination with FOLFIRI and Avastin for second-line treatment of patients with metastatic colorectal cancer (mCRC) with a KRAS mutation.

Near-term Catalyst:

The Company is scheduled to present new clinical data from its phase II trial of Onvansertib in metastatic Castration-Resistant Prostate Cancer (mCRPC) on August 24, 2019.

2. Fulcrum Therapeutics (FULC)

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company developing treatments for genetically-defined diseases with high unmet medical need and an initial focus on rare diseases.

Gained 21.24% to close Monday's trading at $10.96.

News: The Company announced it has initiated a phase IIb clinical trial of its lead drug candidate Losmapimod in facioscapulohumeral muscular dystrophy, dubbed ReDUX4.

Facioscapulohumeral muscular dystrophy is characterized by progressive skeletal muscle loss that initially causes weakness in muscles in the face, shoulders, arms and trunk, and progresses to weakness throughout the lower body.

It is estimated that 16,000 to 38,000 people in the United States have facioscapulohumeral muscular dystrophy. There are no approved therapies for this condition.

Recent event:

The Company went public on the Nasdaq Global Market on July 18, 2019, offering its shares at a price of $16 each.

3. ESSA Pharma Inc. (EPIX)

ESSA is a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer.

Gained 20.53% to close Monday's trading at $1.82.

News: No news

Pipeline:

The Company's lead drug candidate is EPI-7386 for the treatment of metastatic castration-resistant prostate cancer. The IND-enabling studies are under progress, and the Company is on track to enter clinical studies with EPI-7386 in the first quarter of 2020.

4. Ardelyx Inc. (ARDX)

Ardelyx is a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with cardiorenal diseases.

Gained 20.24% to close Monday's trading at $2.97.

News: No news

Pipeline:

The Company's lead drug candidate is Tenapanor, which is being evaluated for the treatment of patients with irritable bowel syndrome with constipation, and for the treatment of hyperphosphatemia in people with end-stage renal disease (ESRD) who are on dialysis. Also in the pipeline is RDX013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease.

Near-term Catalysts:

-- The New Drug Application for Tenapanor for patients with irritable bowel syndrome with constipation is under FDA review, with a decision date set for September 12, 2019.
-- Results from a phase III trial of Tenapanor in combination with phosphate binders to treat hyperphosphatemia in patients with end-stage renal disease (ESRD) who are on dialysis, dubbed AMPLIFY, are currently expected to be announced in the third quarter of 2019.
-- Results from a phase III clinical trial evaluating Tenapanor as a monotherapy treatment for hyperphosphatemia in patients with end-stage renal disease who are on dialysis, dubbed PHREEDOM, are currently expected to be announced in the fourth quarter of 2019.

5. Oncternal Therapeutics Inc. (ONCT)

Oncternal Therapeutics, a clinical-stage oncology company, is the result of the reverse merger between publicly traded GTx, Inc. and privately-held Oncternal Therapeutics Inc.

Gained 18.20% to close Monday's trading at $5.00.

News: No news

Near-term Catalysts:

-- Additional data from its Phase 1/2 study of Cirmtuzumab in combination with Ibrutinib from patients with chronic lymphocytic leukemia are expected to be presented at a scientific conference in the fourth quarter of 2019.
-- Additional data from its Phase 1/2 study of Cirmtuzumab in combination with Ibrutinib from patients with mantle cell lymphoma are expected to be presented at a scientific conference in the fourth quarter of 2019.
-- Data from its Phase 1 study of Cirmtuzumab in combination with Paclitaxel from patients with breast cancer are expected to be presented at a scientific conference in the fourth quarter of 2019.
-- Data from its Phase 1 study of TK216 from patients with Ewing sarcoma are expected to be presented at a scientific conference in the fourth quarter of 2019.

For comments and feedback contact: editorial@rttnews.com

Business News

RELATED NEWS
Follow RTT
>